Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03039790 |
Recruitment Status :
Completed
First Posted : February 1, 2017
Last Update Posted : December 13, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy Volunteers Norovirus | Biological: NoV Vaccine | Phase 2 |
The drug being tested in this study is called NoV vaccine. NoV vaccine is being tested for protection against acute gastroenteritis (AGE) due to norovirus.
The study will enroll maximum of 575 participants. Participants who previously received NoV vaccine in studies NOR-107, NOR-210 and NOR-204 will be enrolled. Participants from study NOR-107 will enter the study at the time of their 3rd year post-primary vaccination, and from studies NOR-210 and NOR-204, at their 2nd year post-primary vaccination. The duration of participation in the study will be different for each participant.
This multi-center trial will be conducted in Belgium and the United States. The overall time to participate in this study is maximum 5 years after primary NoV vaccination. Participants will have a maximum of 4 visits over 3 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 528 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine |
Actual Study Start Date : | February 21, 2017 |
Actual Primary Completion Date : | July 22, 2021 |
Actual Study Completion Date : | July 22, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: NoV Vaccine
Participants who previously received NoV vaccine adjuvanted with aluminum as aluminum hydroxide or with monophosphoryl lipid A (MPL), injection, intramuscularly as planned in studies NOR-107, NOR-210 and NOR-204 will be assessed over 5 years post-primary vaccination. Vaccine formulations according to the parent trials: NOR-107, 210 and 204.
|
Biological: NoV Vaccine
No NoV vaccine injection administered. |
- Geometric Mean Blocking Titers 50 percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies [ Time Frame: Up to 5 years post-primary vaccination ]GMBT50 of anti-norovirus GI. VLP antibody titers as measured by the histo-blood group antigen (HBGA) blocking assay.
- GMBT50 of Anti-norovirus GII.4 VLP Antibodies [ Time Frame: Up to 5 years post-primary vaccination ]GMBT50 of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA blocking assay.
- Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies [ Time Frame: Up to 5 years post-primary vaccination ]GMT of anti-norovirus GI.1 VLP antibody titers as measured by total immunoglobulin (pan-Ig) enzyme-linked immunoassay (ELISA).
- GMT of Anti-norovirus GII.4 VLP Antibodies [ Time Frame: Up to 5 years post-primary vaccination ]GMT of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
1. Male and female participants who previously received at least 1 dose of NoV vaccine in trials NOR-107, NOR-210 and NOR-204, have baseline and post-vaccination data, and completed the primary vaccination trial protocol as initially described.
Exclusion Criteria:
- Participation in any clinical trial is allowed, on condition that no investigational product is administered within 30 days prior to blood sampling.
- In the opinion of the investigator, the participant is not medically eligible to provide blood specimens.
- Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03039790
United States, Alabama | |
Simon-Williamson Clinic/Synexus Clinical Research US, Inc | |
Birmingham, Alabama, United States, 35211 | |
United States, Arizona | |
Synexus Clinical Research US, Inc./Fountain Hills Family Practice, P.C. | |
Fountain Hills, Arizona, United States, 85268 | |
United States, Colorado | |
Synexus Clinical Research US, Inc/Southwest Family Medicine | |
Littleton, Colorado, United States, 80127 | |
United States, Florida | |
Miami Research Associates | |
Miami, Florida, United States, 33143 | |
United States, Kansas | |
Johnson County Clin-Trials | |
Lenexa, Kansas, United States, 66219 | |
United States, Missouri | |
St. Louis University, School of Medicine | |
Saint Louis, Missouri, United States, 63106 | |
United States, New York | |
Regional Clinical Research Inc. | |
Endwell, New York, United States, 13760 | |
University of Rochester | |
Rochester, New York, United States, 14642 | |
United States, Texas | |
Benchmark Research Austin | |
Austin, Texas, United States, 78705 | |
Belgium | |
Universiteit Antwerpen | |
Antwerpen, Belgium, 2610 | |
Universitair Ziekenhuis Gent | |
Gent, Belgium, 9000 |
Study Director: | Medical Director | Takeda |
Responsible Party: | Takeda |
ClinicalTrials.gov Identifier: | NCT03039790 |
Other Study ID Numbers: |
NOR-213 2016-004288-37 ( EudraCT Number ) U1111-1189-7907 ( Registry Identifier: WHO ) |
First Posted: | February 1, 2017 Key Record Dates |
Last Update Posted: | December 13, 2021 |
Last Verified: | December 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) |
Access Criteria: | IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement. |
URL: | https://vivli.org/ourmember/takeda/ |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Drug Therapy |